RxDoctor Payments DataLook up a doctor →

Amber Berleen

Family · Glendale, AZNPI 1851890222

Payments from drug & device makers

$15,844in general payments, 2019–2025

Across 642 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Catalyst Pharmaceuticals, Inc.$1K
  • Novartis$1K
  • Pfizer$905
  • Johnson & Johnson$735
  • Astellas Pharma US Inc$677
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$7004%
  • Travel & lodging$3752%
  • Food & beverage$14,03289%
  • Education$7375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)54$1,383
Catalyst Pharmaceuticals, Inc.3$1,152
Novartis60$1,078
Pfizer51$905
Johnson & Johnson31$735
Astellas Pharma US Inc24$677
Merck27$630
E.r. Squibb & Sons, L.L.C.23$621
Daiichi Sankyo Inc.23$546
AbbVie34$508
Incyte Corporation18$498
Amgen27$471
Sanofi19$413
Jazz Pharmaceuticals Inc.11$396
Genentech USA, Inc.15$351
Seagen Inc.14$339
Lilly USA, LLC13$305
Gilead(2 entities)9$297
Tersera Therapeutics LLC8$236
Bristol Myers Squibb12$226
Exelixis Inc.8$205
Inari Medical, Inc.1$199
Bayer9$189
Eisai Inc.8$178
Takeda Pharmaceuticals U.S.A., Inc.7$177
Pharmaessentia USA Corporation3$171
Genmab U.S., Inc.6$168
Boehringer Ingelheim6$158
Springworks Therapeutics, Inc.5$134
Pharmacyclics LLC, An Abbvie Company7$130
Puma Biotechnology, Inc.7$125
Kyowa Kirin, Inc.6$122
Blueprint Medicines Corporation6$116
Deciphera Pharmaceuticals Inc.5$115
Boston Scientific1$111
Karyopharm Therapeutics Inc.6$106
Adaptive Biotechnologies Corporation5$106
AVEO Pharmaceuticals, Inc.5$104
Array Biopharma Inc5$98
Sobi, Inc4$92
Sanofi-aventis U.S. LLC1$85
Stemline Therapeutics Inc.3$83
Taiho Oncology, Inc.3$78
Rigel Pharmaceuticals, Inc.4$77
Tempus AI, Inc3$77
ADC Therapeutics America, Inc.3$71
Regeneron Healthcare Solutions, Inc.2$69
Syndax Pharmaceuticals, Inc.2$59
Acrotech Biopharma Inc.4$57
GSK3$57
Myovant Sciences Inc.3$56
AMAG Pharmaceuticals, Inc.3$55
EMD Serono, Inc.2$48
Beigene USA, Inc.2$44
Legend Biotech USA Inc.2$43
Coherus Oncology, Inc.2$40
Ipsen Biopharmaceuticals, Inc2$39
Clovis Oncology, Inc.2$35
Sumitomo Pharma America, Inc.1$31
CTI Biopharma Corp.1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,844 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$784
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax21$196,600
EliquisApixaban79$64,759
XareltoRivaroxaban21$21,703
Hydroxyurea37$1,264
Anastrozole37$645
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$596
Oxycodone Hcl13$228
Dexamethasone20$227
Potassium Chloride27$140
Prochlorperazine Maleate14$95
Prednisone19$37
Gabapentin11$27
Lorazepam12$9

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$508$196,60021 claims
PfizerEliquis$905$64,75979 claims
Johnson & JohnsonXarelto$735$21,70321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →